Search
GS030-DP
go.drugbank.com/drugs/DB17847InvestigationalGS030-DP is an optogenetic gene therapy being investigated for the treatment of retinitis pigmentosa. … It is a component of GS030, an investigational optogenetic treatment, in combination with a medical device GS030-MD.[A259816, L46701]
Cisplatin
go.drugbank.com/drugs/DB00515ApprovedInvestigationalCisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung
Categories: OCT2 Substrates with a Narrow Therapeutic Index, Compounds used in a research, industrial, or household settingProducts: CISPLATINO 10 MG POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCIÓN INYECTABLECyclophosphamide
go.drugbank.com/drugs/DB00531ApprovedInvestigationalPrecursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, a...
Categories: Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic IndexProducts: CICLOFOSFAMIDA 1 G POLVO PARA RECONSTITUIR A SOLUCION INYECTABLE, CICLOFOSFAMIDA 200 MG POLVO PARA RECONSTITUIR A SOLUCIÓN INYECTABLE.Estradiol cypionate
go.drugbank.com/drugs/DB13954ApprovedVet approvedEstradiol Cypionate is a pro-drug ester of [DB00783], a naturally occurring hormone that circulates endogenously within the human body. … Because of the difference in potency between estradiol and estrone, menopause (and a change in primary hormone from estradiol to estrone) is associated with a number of symptoms associated with this reduction
Adlinacogene civaparvovec
go.drugbank.com/drugs/DB16788InvestigationalIt uses proprietary zinc finger nuclease (ZFN) genome editing to insert into the DNA of liver cells a copy of the F9 gene, which controls the production of Factor IX.
Peginterferon alfacon-1
go.drugbank.com/drugs/DB05860Experimental[Infergen] is a bio-engineered type I interferon alpha that is FDA-approved for the treatment of patients with chronic hepatitis C infections. … PEGylation is a technology for the chemical attachment of polyethylene glycol (PEG) polymer chains to a broad range of drug substances such as peptides and proteins including antibody fragments; small
BW-A 58C
go.drugbank.com/drugs/DB06740Experimentalmetabolite in man in vivo and also in human liver microsomes, where this is catalysed primarily by a 54 kDa CYP2C9 form of cytochrome P450, P450hB20-27. … BW-A 58C, also known as 2-(4-tert-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone, is an experimental naphthoquinone antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy
Detomidine
go.drugbank.com/drugs/DB11556InvestigationalVet approvedCurrently, it is only approved by the FDA for use in horses but has been studied for use in other large animals. … Detomidine is an α2-adrenergic agonist that is used as a horse sedative. Normally, it is administered in the salt form, detomidine hydrochloride.
Efgartigimod alfa
go.drugbank.com/drugs/DB15270ApprovedInvestigationalEfgartigimod alfa for intravenous use was granted FDA approval on December 17, 2021[L39501] and European Commission approval on August 11, 2022 for use in patients with myasthenia gravis. … [A243759,A243784] Efgartigimod alfa is a first-in-class[L39501] antagonist of the neonatal Fc receptor (FcRn) used in the treatment of MG.
Etryptamine
go.drugbank.com/drugs/DB01546ApprovedIllicitWithdrawnan FDA approved antidepressant under the name Monase. … αET is a stimulant and hallucinogen, but it is less stimulating and hallucinogenic than alpha-methyltryptamine, a closely related compound.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates